NASDAQ:GALT

Galectin Therapeutics Q3 2025 Earnings Results & Report

Galectin Therapeutics logo
$2.91 -0.11 (-3.64%)
As of 11/17/2026 04:00 PM Eastern

Galectin Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.13 versus the -$0.11 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

Galectin Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Q3 2025 Earnings FAQ

Galectin Therapeutics (NASDAQ:GALT) reported earnings of -$0.13 per share for Q3 2025, missing the consensus estimate of -$0.11. The report was announced on Friday, November 14, 2025.

Galectin Therapeutics Earnings Headlines

Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this fall.tc pixel
Galectin Therapeutics Inc GALT
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer.

Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.

View Galectin Therapeutics Profile